Newbury Pharmaceuticals AB (publ) (NEWBRY.ST)
SEK 3.35
(-0.3%)
SEK 3.35
(-0.3%)
| Year | EBITDA | EBITDA Growth |
|---|---|---|
| 2024 | -12.34 Million SEK | 32.69% |
| 2023 | -18.33 Million SEK | -33.05% |
| 2022 | -13.66 Million SEK | -178.0% |
| 2021 | -4.91 Million SEK | 0.0% |
| Year | EBITDA | EBITDA Growth |
|---|---|---|
| 2024 Q2 | -4.14 Million SEK | -51.68% |
| 2024 Q1 | -2.73 Million SEK | 38.81% |
| 2024 Q4 | 2.4 Million SEK | 130.56% |
| 2024 Q3 | -7.86 Million SEK | -89.56% |
| 2023 Q1 | - SEK | 0.0% |
| 2023 Q2 | -4.55 Million SEK | 0.0% |
| 2023 FY | - SEK | -33.05% |
| 2023 Q3 | -3.87 Million SEK | 14.9% |
| 2023 Q4 | -4.31 Million SEK | -11.36% |
| 2022 FY | - SEK | -178.0% |
| 2021 FY | - SEK | 0.0% |
| Name | EBITDA | EBITDA Difference |
|---|---|---|
| AcuCort AB | -13.69 Million SEK | 9.868% |
| AlzeCure Pharma AB (publ) | -37.86 Million SEK | 67.413% |
| BioGaia AB (publ) | 466.19 Million SEK | 102.647% |
| Enzymatica AB (publ) | -41.12 Million SEK | 69.992% |
| Enorama Pharma AB (publ) | -43.05 Million SEK | 71.338% |
| Gabather AB (publ) | 37 Thousand SEK | 33451.351% |
| Klaria Pharma Holding AB (publ.) | -14.77 Million SEK | 16.452% |
| Moberg Pharma AB (publ) | -26.95 Million SEK | 54.227% |
| Nanexa AB (publ) | -70.79 Million SEK | 82.568% |
| ODI Pharma AB | 1.36 Million SEK | 1002.467% |
| Orexo AB (publ) | -22 Million SEK | 43.909% |
| Probi AB (publ) | 115.61 Million SEK | 110.674% |
| Swedencare AB (publ) | 484 Million SEK | 102.55% |
| Swedish Orphan Biovitrum AB (publ) | 7.23 Billion SEK | 100.171% |
| Toleranzia AB | -7.39 Million SEK | -66.802% |
| Vivesto AB | -89.75 Million SEK | 86.252% |